Tag - BLU-5937

BELLUS Health (TSX:BLU) enrolled the first patient in its Phase 2 study of BLU-5937 for the treatment of chronic cough. The study, called RELIEF, will assess the efficacy, safety, and tolerability of BLU-5937 at four...